The role of rituximab in a case of EBV-related lymphoproliferative disease presenting with haemophagocytosis.
Bosman
G
G
Langemeijer
S M C
SM
Hebeda
K M
KM
Raemaekers
J M M
JM
Pickkers
P
P
van der Velden
W J F M
WJ
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy* / Q000821:virology; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D051359:Lymphohistiocytosis, Hemophagocytic / Q000188:drug therapy* / Q000821:virology; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone